Contact lenses that deliver medications directly to the eye over a period of days or weeks was the recent grand prize winner of Massachusetts Institute of Technology’s Sloan Healthcare Innovation Prize. The MIT Sloan Healthcare Innovation Prize competition had 8 finalists who pitched their healthcare innovations to judges from Optum and other local venture firms, […]
Glaucoma
Allergan gel-based stents are treating glaucoma
An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat […]
ForSight Vision5’s Helios implant delivers at 6 months in Phase II trial
The Helios drug-eluting implant developed by ForSight Vision5 lowered intraocular pressure in glaucoma patients by about 20% after 6 months, according to study results published today in Ophthalmology, the journal of the American Academy of Ophthalmology. The Helios device is a thin, silicone ring impregnated with the glaucoma drug bimatoprost that’s designed to slowly release the drug […]
iStar Medical raises $11m Series B for glaucoma implant
iStar Medical said today that it raised a $11.4 million Series B round for the implants it’s developing to treat glaucoma. Wavre, Belgium-based iStar said its pipeline, including the 1st-generation StarFlo implant, is based on the Star material it created. The €10 million Series B round will go toward the development and CE Mark trial of its 2nd-generation […]
Transcend Medical touts data, plans FDA filing for CyPass glaucoma stent
Glaucoma treatment: InFocus meets enrollment goal on MicroShunt clinical trial

InnFocus has reached its goal of enrolling 75 patients in a Phase I clinical study for its MicroShunt glaucoma eye-drainage implant.
The device is used to help reduce pressure within the eye in patients with glaucoma. The product is intended to be an alternative to traditional glaucoma surgery.
Implandata raises €3m, creates U.S. subsidiary
Ivantis adds $25M, eyes U.S. approval for glaucoma micro-stent
Ivantis today said it added a $25 million tranche to its now $71 million Series B round as the Irvine, Calif.-based company looks to bring its miniature glaucoma scaffold to the U.S. market.